Favourable prognostic role of histological regression in stage III positive sentinel lymph node melanoma patients

被引:18
作者
Zugna, D. [1 ]
Senetta, R. [2 ]
Osella-Abate, S. [2 ]
Fierro, M. T. [3 ]
Pisacane, A. [4 ]
Zaccagna, A. [5 ]
Sapino, A. [4 ]
Bataille, V. [6 ,7 ]
Maurichi, A. [8 ]
Picciotto, F. [9 ]
Cassoni, P. [2 ]
Quaglino, P. [3 ]
Ribero, S. [3 ]
机构
[1] Univ Turin, CERMS, Unit Canc Epidemiol, Dept Med Sci, CSo Dogliotti 14, I-10126 Turin, Italy
[2] Univ Turin, Sect Surg Pathol, Dept Med Sci, CSo Dogliotti 14, I-10126 Turin, Italy
[3] Univ Turin, Sect Dermatol, Dept Med Sci, CSo Dogliotti 14, I-10126 Turin, Italy
[4] FPO, Candiolo Canc Inst IRCCS, Pathol Unit, Km 3,95,SP142, I-10060 Turin, Italy
[5] FPO, Candiolo Canc Inst IRCCS, Dermatol Surg Sect, Km 3,95,SP142, I-10060 Turin, Italy
[6] Mt Vernon Canc Ctr, Rickmansworth Rd, Northwood HA6 2RN, Middx, England
[7] Kings Coll London, Dept Twin Res & Genet Epidemiol, South Wing Block D,Westminster Bridge Rd, London SE1 7EH, England
[8] Fdn IRCCS Ist Nazl Tumouri, Melanoma & Sarcoma Surg Unit, Via Giacomo Venezian 1, I-20133 Milan, Italy
[9] AOU Citta Salute & Sci Torino, Dept Oncol, Dermatol Surg Sect, Via Cherasco 23, I-10123 Turin, Italy
关键词
histological regression; sentinel lymph node; survival stage III; melanoma; THIN MALIGNANT MELANOMAS; CUTANEOUS MELANOMA; BASIN DRAINAGE; COMPETING RISK; METASTASES; LYMPHADENECTOMY; CONCORDANCE; RELEVANCE; THICKNESS; MODEL;
D O I
10.1038/bjc.2017.397
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Sentinel lymph node (SLN)-positive melanoma patients are a heterogeneous group of patients with survival rates ranging from similar to 20 to over 80%. No data are reported concerning the role of histological regression on survival in stage III melanoma. Methods: The study included 365 patients with positive SLN from two distinct hospitals. The model was developed on patients from 'AOU Citta della Salute e della Scienza di Torino', and externally validated on patients from IRCCS of Candiolo. Survival analyses were carried out according to the presence of regression and adjusted for all other prognostic factors. Results: Among patients followed at 'AOU Citta della Salute e della Scienza di Torino' (n = 264), the median follow-up time to death or censoring (whatever two events occurred earlier) was 2.7 years since diagnosis (interquartile range: 1.3-5.8). In all, 79 patients died from melanoma and 11 from other causes. Histological regression (n = 43) was associated with a better prognosis (sub-HR = 0.34, CI 0.12-0.92), whereas the other factors above showed an inverse association. In the external validation, the concordance index was 0.97 at 1 year and decreased to 0.66 at 3 years and to 0.59 at 5 years. Adding histological regression in the prognostic model increased the discriminative ability to 0.75 at 3 years and to 0.62 at 5 years. Finally, using a cutoff of 20% for the risk of death led to a net re-classification improvement of 15 and 11% at 3 and 5 years after diagnosis, respectively. Conclusions: Histological regression could lead to an improvement in prognostic prediction in patients with stage III-positive SLN melanoma.
引用
收藏
页码:398 / 404
页数:7
相关论文
共 38 条
  • [1] [Anonymous], 2015, PROT EX SPEC PAT MEL
  • [2] Age as a Prognostic Factor in Patients with Localized Melanoma and Regional Metastases
    Balch, Charles M.
    Soong, Seng-Jaw
    Gershenwald, Jeffrey E.
    Thompson, John F.
    Coit, Daniel G.
    Atkins, Michael B.
    Ding, Shouluan
    Cochran, Alistair J.
    Eggermont, Alexander M. M.
    Flaherty, Keith T.
    Gimotty, Phyllis A.
    Johnson, Timothy M.
    Kirkwood, John M.
    Leong, Stanley P.
    McMasters, Kelly M.
    Mihm, Martin C., Jr.
    Morton, Donald L.
    Ross, Merrick I.
    Sondak, Vernon K.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2013, 20 (12) : 3961 - 3968
  • [3] Final Version of 2009 AJCC Melanoma Staging and Classification
    Balch, Charles M.
    Gershenwald, Jeffrey E.
    Soong, Seng-jaw
    Thompson, John F.
    Atkins, Michael B.
    Byrd, David R.
    Buzaid, Antonio C.
    Cochran, Alistair J.
    Coit, Daniel G.
    Ding, Shouluan
    Eggermont, Alexander M.
    Flaherty, Keith T.
    Gimotty, Phyllis A.
    Kirkwood, John M.
    McMasters, Kelly M.
    Mihm, Martin C., Jr.
    Morton, Donald L.
    Ross, Merrick I.
    Sober, Arthur J.
    Sondak, Vernon K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (36) : 6199 - 6206
  • [4] Identification of Patients with Intermediate Thickness Melanoma at Low Risk for Sentinel Lymph Node Positivity
    Bartlett, Edmund K.
    Peters, Madalyn G.
    Blair, Anne
    Etherington, Mark S.
    Elder, David E.
    Xu, Xiaowei G.
    Guerry, DuPont
    Ming, Michael E.
    Fraker, Douglas L.
    Czerniecki, Brian J.
    Gimotty, Phyllis A.
    Karakousis, Giorgos C.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2016, 23 (01) : 250 - 256
  • [5] THIN MALIGNANT MELANOMAS (LESS-THAN-1.5 MM) WITH METASTASIS - A HISTOLOGICAL STUDY AND SURVIVAL ANALYSIS
    BLESSING, K
    MCLAREN, KM
    MCLEAN, A
    DAVIDSON, P
    [J]. HISTOPATHOLOGY, 1990, 17 (05) : 389 - 395
  • [6] Cochran AJ, 2000, CANCER, V89, P236, DOI 10.1002/1097-0142(20000715)89:2<236::AID-CNCR5>3.0.CO
  • [7] 2-0
  • [8] Pathology of sentinel lymph nodes for melanoma
    Cook, M. G.
    Di Palma, S.
    [J]. JOURNAL OF CLINICAL PATHOLOGY, 2008, 61 (08) : 897 - 902
  • [9] A proportional hazards model for the subdistribution of a competing risk
    Fine, JP
    Gray, RJ
    [J]. JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1999, 94 (446) : 496 - 509
  • [10] Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline
    Garbe, Claus
    Peris, Ketty
    Hauschild, Axel
    Saiag, Philippe
    Middleton, Mark
    Spatz, Alain
    Grob, Jean-Jacques
    Malvehy, Josep
    Newton-Bishop, Julia
    Stratigos, Alexander
    Pehamberger, Hubert
    Eggermont, Alexander
    [J]. EUROPEAN JOURNAL OF CANCER, 2010, 46 (02) : 270 - 283